All In Biotech

Drug Trial Radar · NCT05320588

A Study in Patients With Advanced Cancers

A Phase 1/2 Study of BIO-106 As Monotherapy or In Combination With Pembrolizumab in Patients With Advanced Cancers (StarBridge-1)

Last checked: Nov 19, 2026Latest source record: Jul 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

332

Planned (sponsor's estimate)

Start

Mar 25, 2022

Primary completion

Apr 2024

Study completion Apr 2027

Sponsor

Lead sponsor
BiOneCure Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Apr 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.

Conditions

  • Advanced Cancer
  • Advanced Solid Tumor
  • Cancer
  • Oncology

Interventions

  • BIO-106Drug

    BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)

  • PembrolizumabDrug

    Programmed death receptor-1 (PD 1)-blocking antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)Time frame: 1 year
  2. Incidence and nature of dose-limiting toxicities (DLTs) - (Phase 1)Time frame: up to 21 days
  3. Maximum tolerable dose (MTD) or a tolerated dose below MTD - (Phase 1)Time frame: 1 year
  4. Anti-tumor activity by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) - (Phase 2)Time frame: 2 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • NEXT Oncology Austin

    Austin, Texas · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.